<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:chebi fb="0" ids="5441">Glibenclamide</z:chebi> improves outcomes in rat models of <z:hpo ids='HP_0001297'>stroke</z:hpo>, with treatment as late as 6 h after <z:hpo ids='HP_0003674'>onset</z:hpo> of <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> shown to be beneficial </plain></SENT>
<SENT sid="1" pm="."><plain>Because the molecular target of <z:chebi fb="0" ids="5441">glibenclamide</z:chebi>, the <z:chebi fb="0" ids="26831">sulfonylurea</z:chebi> receptor 1 (Sur1)-regulated NC(Ca-ATP) channel, is upregulated de novo by a complex transcriptional mechanism, and the principal pathophysiological target, <z:e sem="disease" ids="C1527311" disease_type="Disease or Syndrome" abbrv="">brain swelling</z:e>, requires hours to develop, we hypothesized that the treatment window would exceed 6 h </plain></SENT>
<SENT sid="2" pm="."><plain>We studied a clinically relevant rat model of <z:hpo ids='HP_0001297'>stroke</z:hpo> in which middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> (75% &lt; reduction in LDF signal ≤90%) was produced using an intra-arterial occluder </plain></SENT>
<SENT sid="3" pm="."><plain>Recanalization was obtained 4.5 h later by removing the occluder </plain></SENT>
<SENT sid="4" pm="."><plain>At that time, we administered recombinant tissue plasminogen activator (rtPA; 0.9 mg/kg IV over 30 min) </plain></SENT>
<SENT sid="5" pm="."><plain>Immunolabeling showed modest expression of Sur1 5 h after <z:hpo ids='HP_0003674'>onset</z:hpo> of <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e>, with expression increasing 7- to 11-fold (P &lt; 0.01) by 24 h </plain></SENT>
<SENT sid="6" pm="."><plain>Rats were administered either vehicle or <z:chebi fb="0" ids="5441">glibenclamide</z:chebi> (10 μg/kg IP loading dose plus 200 ng/h by constant subcutaneous infusion) beginning 4.5 or 10 h after <z:hpo ids='HP_0003674'>onset</z:hpo> of <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> </plain></SENT>
<SENT sid="7" pm="."><plain>In rats treated at 4.5 or 10 h, <z:chebi fb="0" ids="5441">glibenclamide</z:chebi> significantly reduced hemispheric swelling at 24 h from (mean ± <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">SEM</z:e>) 14.7 ± 1.5% to 8.1 ± 1.6% or 8.8 ± 1.1% (both P &lt; 0.01), respectively, and significantly reduced 48-h mortality from 53% to 17% or 12% (both P &lt; 0.01), and improved Garcia scores at 48 h from 3.8 ± 0.62 to 7.6 ± 0.70 or 8.4 ± 0.74 (both P &lt; 0.01) </plain></SENT>
<SENT sid="8" pm="."><plain>We conclude that, in a clinically relevant model of <z:hpo ids='HP_0001297'>stroke</z:hpo>, the treatment window for <z:chebi fb="0" ids="5441">glibenclamide</z:chebi> extends to 10 h after <z:hpo ids='HP_0003674'>onset</z:hpo> of <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> </plain></SENT>
</text></document>